Title: „Precision Oncology based on Gene-Drug Screening“

Speaker: Prof Do-Hyun Nam
Dept. of Neurosurgery,
Refactory Cancer Department
Samsung Medical Center
When: 09th of October 2019
Where: Hörsaalzentrum, HS E2, Auenbruggerplatz 15/2. UG, 8036 Graz
Time: 13:15-14:45

Existing efforts in personalized medicine to evaluate the potential efficacy of a treatment are largely focused on identifying genomic predictors of response. However, such approaches have limitations since most of refractory solid cancers have a multitude of genetic aberrations with profound molecular heterogeneity, and prediction of therapeutic response is based on indirect evidence from unrelated cancer cell lines. Sustainable clinical success in precision oncology is more likely to be achieved by an integrated approach consisting of genomics and the **patient cell-based drug screening.**
For implementation of this innovative platform of precision medicine, we have established pharmacological landscapes of 462 patient-derived tumor cells (PDCs) across 14 cancer types, together with genomic and transcriptomic profiling in 385 of these tumors (Nat Gen 2018). Here, we have established a drug screening system with the in vitro sensitivities of 60 targeted cancer drugs under clinical and preclinical investigation.



Ref: (2019-08-21 Scientific argumentaion (CBmed).pdf)